Dicot (DICOT) Q1 2026 earnings summary

Executive summary

• Focused on advancing LIB-01, a novel erectile dysfunction drug, with preparations for a phase 2b study in the US and Europe set for the second half of 2026.

• Successfully developed a tablet formulation of LIB-01 and began manufacturing for clinical trials.

• Announced a planned rights issue of SEK 210 million, 80% secured, to fully fund the phase 2b study.

• Strong institutional and investor interest, with participation in major industry conferences.

Financial highlights

• Net sales were SEK 0.0 million for the quarter, unchanged year-over-year.

• Result after financial items was SEK -14.8 million, improved from SEK -22.9 million in Q1 2025.

• Earnings per share remained at SEK -0.01, unchanged from the same quarter last year.

• Operating expenses decreased to SEK 15.1 million from SEK 23.6 million year-over-year.

• Cash and cash equivalents at quarter-end were SEK 56.2 million, down from SEK 92.8 million a year earlier.

Outlook and guidance

• Phase 2b clinical trial for LIB-01 planned to start in the second half of 2026 in the US and Europe.

• Rights issue of SEK 210 million, 80% secured, will provide full funding for the phase 2b study.

• Continued focus on out-licensing and industrial partnerships to support future phase 3 financing.